Aeglea Cuts Majority of Staff Following Mixed Trial Results
Following mixed Phase I/II data for its homocystinuria hopeful pegtarviliase, Aeglea lays off all but 10 employees and launches a sweeping strategic review.
Aeglea Cuts Majority of Staff Following Mixed Trial Results Read More »
